Alternative molecular formats and therapeutic applications for bispecific antibodies

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610

Single-Chain Antigen-Binding Proteins

Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522

The therapeutic monoclonal antibody market

Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,369

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P., & Winter, G. P. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,010

Biopharmaceutical benchmarks 2014

Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008

Macromolecular Modeling with Rosetta

Das, R., & Baker, D. A. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.062906.171838 · Cited by 995

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

Kolfschoten, M. V. D. N., Schuurman, J., Losen, M. H., Bleeker, W. K., Martínez‐Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 981

Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

Saphire, E. O., Parren, P. W. H. I., Pantophlet, R. A., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 959

Bispecific antibodies: a mechanistic review of the pipeline

Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303

The making of bispecific antibodies

Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 961

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780

Immunotherapy for glioma: Current management and future application

Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 754

T cell-engaging therapies — BiTEs and beyond

Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 675

Antibody Structure and Function: The Basis for Engineering Therapeutics

Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 623

Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics

Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 451

mRNA therapeutics in cancer immunotherapy

Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 317

Considerations for the Design of Antibody-Based Therapeutics

Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 328

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299

Bispecific antibodies: design, therapy, perspectives

Sedykh, S. E., Prinz, V. Y., Buneva, V. N., & Nevinsky, G. A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 297

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290

Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

Xenaki, K. T., Oliveira, S., & Henegouwen, P. M. P. V. B. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 301

Bispecific antibodies and their applications

Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 289

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 292

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 296

NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives

Nigro, C. L., Macagno, M., Sangiolo, D., Bertolaccini, L., Aglietta, M., & Merlano, M. C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.42 · Cited by 273

CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment

Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 240

Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

Cruz, E., & Kayser, V. (2019) · Biologics · doi:10.2147/btt.s166310 · Cited by 245

Challenges and opportunities for non-antibody scaffold drugs

Vazquez-Lombardi, R., Phan, T. G., Zimmermann, C., Lowe, D., Jermutus, L., & Christ, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.004 · Cited by 236

New immune cell engagers for cancer immunotherapy

Fenis, A., Demaria, O., Gauthier, L., Vivier, É., & Narni-Mancinelli, É. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00982-7 · Cited by 214

How mRNA therapeutics are entering the monoclonal antibody field

Van Hoecke, L., & Roose, K. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1804-8 · Cited by 205

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

Hutchings, C. J., Koglin, M., Olson, W. C., & Marshall, F. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.91 · Cited by 202

Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety

Ellerman, D. A. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.026 · Cited by 200

Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment

Kintzing, J. R., Interrante, M. V. F., & Cochran, J. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.005 · Cited by 199

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

Klein, C., Schäfer, W. M., & Regula, J. T. (2016) · mAbs · doi:10.1080/19420862.2016.1197457 · Cited by 186

Redirecting T cells to hematological malignancies with bispecific antibodies

Velasquez, M. P., Bonifant, C. L., & Gottschalk, S. M. (2017) · Blood · doi:10.1182/blood-2017-06-741058 · Cited by 176

Antibody therapeutics and immunoregulation in cancer and autoimmune disease

Yasunaga, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.001 · Cited by 168

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

Smith, E., Olson, K., Haber, L., Varghese, B., Duramad, P., Tustian, A. D., Oyejide, A., Kirshner, J. R., Canova, L., Menon, J., et al. (2015) · Scientific Reports · doi:10.1038/srep17943 · Cited by 167

Engineering antibody therapeutics

Chiu, M. L., & Gilliland, G. L. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.012 · Cited by 175

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

Runcie, K. D., Budman, D. R., John, V. S., & Seetharamu, N. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0051-4 · Cited by 165

Antibody Engineering for Pursuing a Healthier Future

Saeed, A. F. U. H., Wang, R., Ling, S., & Wang, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00495 · Cited by 154

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics

Wu, Z., & Cheung, N. V. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.005 · Cited by 152

Recent advances of bispecific antibodies in solid tumors

Yu, S., Li, A., Liu, Q., Yuan, X., Xu, H., Jiao, D., Pestell, R. G., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0522-z · Cited by 152

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 146

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016) · Cell · doi:10.1016/j.cell.2016.04.050 · Cited by 146

Engineering therapeutic bispecific antibodies using CrossMab technology

Klein, C., Schäfer, W. M., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2018) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 148

Current methods for the synthesis of homogeneous antibody–drug conjugates

Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142

Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments

Demaria, O., Gauthier, L., Debroas, G., & Vivier, É. (2021) · European Journal of Immunology · doi:10.1002/eji.202048953 · Cited by 152

Decoding mechanisms by which silent codon changes influence protein biogenesis and function

Bali, V., & Bebok, Z. M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.03.011 · Cited by 136

mRNA as novel technology for passive immunotherapy

Schlake, T., Theß, A., Thran, M., & Jordan, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 135

Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models

Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

Mazor, Y., Sachsenmeier, K. F., Yang, C., Hansen, A. M., Filderman, J. N., Mulgrew, K. A., Wu, H., & Dall’Acqua, W. F. (2017) · Scientific Reports · doi:10.1038/srep40098 · Cited by 128

Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations

Kholodenko, R. V., Kalinovsky, D. V., Doronin, I. I., Ponomarev, E. D., & Kholodenko, I. V. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170817152554 · Cited by 125

Antibody and antibody fragments for cancer immunotherapy

Chen, W., Yang, Y., & Jiang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.021 · Cited by 123

Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics

Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.06.024 · Cited by 120

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Haber, L., Olson, K., Kelly, M. P., Crawford, A., DiLillo, D. J., Tavaré, R., Ullman, E., Mao, S., Canova, L., Sineshchekova, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93842-0 · Cited by 120

Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment

Chu, C., Su, M., Zhu, J. X., Li, D., Cheng, H., Chen, X. S., & Liu, G. (2019) · Theranostics · doi:10.7150/thno.33539 · Cited by 118

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116

A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses

Wec, A. Z., Nyakatura, E. K., Herbert, A. S., Howell, K. A., Holtsberg, F. W., Bakken, R. R., Mittler, E., Christin, J. R., Shulenin, S., Jangra, R. K., et al. (2016) · Science · doi:10.1126/science.aag3267 · Cited by 113

An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection

Saber, H., Valle, P. D., Ricks, T. K., & Leighton, J. K. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.09.001 · Cited by 108

The development of bispecific antibodies and their applications in tumor immune escape

Zhang, X., Yang, Y., Fan, D., & Xiong, D. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0072-7 · Cited by 112

When liposomes met antibodies: Drug delivery and beyond

Di, J., Xie, F., & Xu, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.003 · Cited by 109

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Liu, H., Saxena, A., Sidhu, S. S., & Wu, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 114

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies

Park, J. A., & Cheung, N. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 105

New emerging targets in cancer immunotherapy: the role of TIM3

Friedlaender, A., Addeo, A., & Banna, G. L. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000497 · Cited by 105

Cellular cytotoxicity is a form of immunogenic cell death

Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 106

Breast cancer immunotherapy: Current and novel approaches

Barzaman, K., Moradi‐Kalbolandi, S., Hosseinzadeh, A., Kazemi, M. H., Khorramdelazad, H., Safari, E., & Farahmand, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107886 · Cited by 100

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 102

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Jiang, H., Ni, H., Zhang, P., Guo, X., Wu, M., Shen, H., Wang, J., Wu, W., Wu, Z., Ding, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1943180 · Cited by 102

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement

Sarker, A., Dhama, N., & Gupta, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200195 · Cited by 104

Coming-of-Age of Antibodies in Cancer Therapeutics

Ayyar, B. V., Arora, S., & O’Kennedy, R. J. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.09.005 · Cited by 99

High concentration formulation developability approaches and considerations

Zarzar, J., Khan, T. A., Bhagawati, M., Weiche, B., Sydow-Andersen, J., & Sreedhara, A. (2023) · mAbs · doi:10.1080/19420862.2023.2211185 · Cited by 94

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

Ha, J.-H., Kim, J.-E., & Kim, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00394 · Cited by 92

Fifty years of monoclonals: the past, present and future of antibody therapeutics

Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104

Recent advances and challenges of bispecific antibodies in solid tumors

Wu, Y., Yi, M., Zhu, S., Wang, H., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00250-1 · Cited by 93

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies

Lejeune, M., Köse, M. C., Duray, E., Einsele, H., Beguin, Y. P., & Caers, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00762 · Cited by 88

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Vafa, O., & Trinklein, N. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00446 · Cited by 82

Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

Chang, C., Wang, Y., Li, R., Rossi, D. L., Liu, D., Rossi, E. A., Cardillo, T. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3431 · Cited by 87

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 85

Structural basis of a novel heterodimeric Fc for bispecific antibody production

Wei, H., Cai, H., Jin, Y., Wang, P., Zhang, Q., Lin, Y., Wang, W., Cheng, J., Zeng, N., Xu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17558 · Cited by 81

Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies

Dickopf, S., Georges, G. J., & Brinkmann, U. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.05.006 · Cited by 89

Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation

Nixon, J. V., Newbold, P., Mustelin, T., Anderson, G. P., & Kolbeck, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.016 · Cited by 83

Cell-surface proteomics for the identification of novel therapeutic targets in cancer

Kuhlmann, L., Cummins, E., Samudio, I. J., & Kislinger, T. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1429924 · Cited by 85

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies

Santich, B. H., Park, J. A., Tran, H., Guo, H.-F., Huse, M., & Cheung, N. V. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax1315 · Cited by 83

Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review

Salama, A. (2015) · Transfusion Medicine and Hemotherapy · doi:10.1159/000438731 · Cited by 80

Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation

Hettich, M., Lahoti, J., Prasad, S., & Niedermann, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3451 · Cited by 79

Bispecific Antibodies in the Treatment of Hematologic Malignancies

Duell, J., Lammers, P. E., Djuretic, I. M., Chunyk, A. G., Alekar, S., Jacobs, I. A., & Gill, S. I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1396 · Cited by 79

CD28 co-stimulation: novel insights and applications in cancer immunotherapy

Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 86

Immuno-targeting the multifunctional CD38 using nanobody

Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 75

Clinical Pharmacology and Translational Aspects of Bispecific Antibodies

Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Hosseini, S. S., Khalili, S., Baradaran, B., Bidar, N., Shahbazi, M., Mosafer, J., Hashemzaei, M., Mokhtarzadeh, A., & Hamblin, M. R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.058 · Cited by 76

Emerging Trends in Immunotherapy for Cancer

Mishra, A., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 79

Design and engineering of bispecific antibodies: insights and practical considerations

Madsen, A. V., Pedersen, L. E., Kristensen, P. K., & Goletz, S. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1352014 · Cited by 79

Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

Ahamadi-Fesharaki, R., Fateh, A., Vaziri, F., Solgi, G., Siadat, S. D., Mahboudi, F., & Jamnani, F. R. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.02.004 · Cited by 76

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells

Dillon, M., Yin, Y., Zhou, J., McCarty, L., Ellerman, D., Slaga, D., Junttila, T. T., Han, G., Sandoval, W., Ovacik, M. A., et al. (2017) · mAbs · doi:10.1080/19420862.2016.1267089 · Cited by 75

2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 3 – Lba, Biomarkers and Immunogenicity)

Amaravadi, L. S., Song, A., Myler, H. A., Thway, T. M., Kirshner, S., Devanarayan, V., Ni, Y. G., Garofolo, F., Birnboeck, H., Richards, S. M., et al. (2015) · Bioanalysis · doi:10.4155/bio.15.226 · Cited by 74

Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 75

Good modeling practice for industrial chromatography: Mechanistic modeling of ion exchange chromatography of a bispecific antibody

Rischawy, F., Saleh, D., Hahn, T., Oelmeier, S. A., Spitz, J., & Kluters, S. (2019) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2019.106532 · Cited by 71

T Cell–Activating Bispecific Antibodies in Cancer Therapy

Trabolsi, A., Arumov, A., & Schatz, J. H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900496 · Cited by 71

Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy

Privitera, G., Pugliese, D., Onali, S., Petito, V., Scaldaferri, F., Gasbarrini, A., Danese, S., & Armuzzi, A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102832 · Cited by 70

Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency

Wang, L., Hoseini, S. S., Xu, H., Ponomarev, V., & Cheung, N. V. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0121 · Cited by 69

Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity

Kotanides, H., Li, Y. H., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I. V., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 66

Bispecific antibodies in haematological malignancies

Viardot, A., & Bargou, R. C. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.002 · Cited by 69

Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases

Rolin, C., Zimmer, J., & Seguin‐Devaux, C. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01176-4 · Cited by 66

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

Ellwanger, K., Reusch, U., Fucek, I., Wingert, S., Ross, T., Müller, T. R., Schniegler‐Mattox, U., Haneke, T., Rajkovic, E., Koch, J., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1616506 · Cited by 66

Evolution of phage display technology: from discovery to application

Rahbarnia, L., Farajnia, S., Babaei, H., Majidi, J., Veisi, K., Ahmadzadeh, V., & Akbari, B. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1258570 · Cited by 68

283 The trifunctional antibody catumaxomab: mode of action

Seimetz, D., Linke, R., Atz, J., Essing, M. M., & Klein, A. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)71088-0

Bispecific antibodies and their applications

Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 289

Bispecific Antibodies: Progress and Application

Habeeb, A., & Hajree, S. (2018) · International Journal of Health Sciences and Research

Bispecific and Multivalent Antibodies - New Swords to Combat Hematological Malignancies

Stanglmaier, M., & Heß, J. (2016) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681081816116020004

Recombinant Bispecific Antibodies for Cancer Therapy

Müller, D., & Kontermann, R. E. (2011) · Cell engineering · doi:10.1007/978-94-007-1257-7_11 · Cited by 2